Novartis inks $925M Anthos takeover to buy back phase 3 clot-busting candidate

Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, Novartis has struck a deal to buy Anthos for $925 million upfront to add the clot-busting prospect to its late-phase pipeline.